curasan AG: Worldwide distribution rights for Epi-Guide®

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

cooperations

Kleinostheim (euro adhoc) - curasan AG (WKN 549 453 8) has been
granted worldwide distribution rights by Kensey Nash Corporation,
USA, for Epi-Guide®, their bioresorbable membrane. This is an
extension to a cooperation established in 2001 which has, so far,
comprised sales in Germany, several other European countries and -
since 2005 - the United States.

"International distribution rights open up additional revenue
potential and create synergies in the expansion of marketing
activities by way of supra-regional opinion leaders and by offering
our distributors an even more balanced, and thus more attractive,
product range", says Chairman Hans Dieter Roessler.

Epi-Guide® is a uniquely structured bioresorbable synthetic membrane
with many applications within guided tissue regeneration (GTR) and
guided bone regeneration (GBR). Suggestions for improvement, made to
the manufacturer by curasan, significantly contributed to the
development of a new generation of membranes which is now available
as an optimized product.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an
exchange-listed company, is a leading innovator within the growth
market of bone and tissue regeneration. The company has developed a
comprehensive product range centred around its synthetic bone
regeneration material Cerasorb®, for use in soft and hard tissue.
With the REVOIS® implant system, the company's sales is focusing more
prominently on the growth market of dental surgery/implantology. The
majority of new products emerging from the substantial development
pipeline are to be offered under licence within other medical fields.
Please visit curasan's corporate website at www.curasan.com

end of announcement euro adhoc 26.03.2007 11:03:00
--------------------------------------------------------------------------------

ots Originaltext: Curasan AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Dr. Erwin Amashaufer, curasan AG, phone +49 6027 4686-465, email:
ir@curasan.de
Andrea Weidner, curasan AG, phone +49 6027 4686-467, email: pr@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade